AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1312
- Registration Number
- NCT00251979
- Locations
- 🇬🇧
Research Site, Leeds, United Kingdom
Nexium Dyspepsia/AST
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT00251992
- Locations
- 🇬🇧
Research Site, Watford, United Kingdom
Chest Pain Pilot Study
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT00251901
- Locations
- 🇸🇪
Research Site, Östersund, Sweden
Esomeprazole (NEXIUM) vs. Surgery
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 626
- Registration Number
- NCT00251927
- Locations
- 🇬🇧
Research Site, Salford, United Kingdom
Nexium Dyspepsia/AST
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00251914
- Locations
- 🇨🇭
Research Site, St. Gallen, Switzerland
GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
Phase 3
Terminated
- Conditions
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2008-03-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 555
- Registration Number
- NCT00251940
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 77
- Registration Number
- NCT00247481
- Locations
- 🇫🇷
Research Site, Villejuif Cedex, France
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00246922
- Locations
- 🇯🇵
Nycomed Japan and Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2008-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT00246974
- Locations
- 🇩🇪
Research Site, Ulm, Germany
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-01
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00246935
- Locations
- 🇯🇵
Nycomed in Japan and Mitsubishi Tanabe Pharma Corporation, Osaka, Japan
© Copyright 2024. All Rights Reserved by MedPath